Literature DB >> 1335217

A placebo-controlled trial of buspirone in anxious inpatient alcoholics.

R Malcolm1, R F Anton, C L Randall, A Johnston, K Brady, A Thevos.   

Abstract

The present study is a double-blind control trial of buspirone versus placebo in highly anxious alcoholics who recently completed inpatient detoxification for alcoholism. Subjects met DSM-III-R criteria for generalized anxiety syndrome and/or other nonpanic forms of anxiety disorders and alcohol dependence. Male veterans aged 21 to 65 were randomized to 45 to 60 mg/day of buspirone (n = 33) or placebo (n = 34). Anxiety scores, as measured by the Hamilton Anxiety Scale and other anxiety measures, declined significantly for both groups, but there were no differential group differences throughout the 6-month treatment period. Survival analysis measuring time to study drop out, time to first drink, time to 5 consecutive drinking days, and time to first intoxication indicated no significant differences between groups. The number of standard drinks per drinking day for nonabstainers also did not differ between groups. In the present study anxious alcoholics taking buspirone did not receive any benefit over placebo on a number of anxiety and alcohol use measures.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1335217     DOI: 10.1111/j.1530-0277.1992.tb00691.x

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  24 in total

Review 1.  Pharmacotherapy of alcohol use disorders: seventy-five years of progress.

Authors:  Leah R Zindel; Henry R Kranzler
Journal:  J Stud Alcohol Drugs Suppl       Date:  2014

2.  Meta-analysis of supplemental treatment for depressive and anxiety disorders in patients being treated for alcohol dependence.

Authors:  Jennifer D J Hobbs; Matt G Kushner; Susanne S Lee; Sean M Reardon; Eric W Maurer
Journal:  Am J Addict       Date:  2011-05-31

3.  A 5-HT1A agonist and a 5-HT2c antagonist reduce social interaction deficit induced by multiple ethanol withdrawals in rats.

Authors:  David H Overstreet; Darin J Knapp; Sheryl S Moy; George R Breese
Journal:  Psychopharmacology (Berl)       Date:  2003-04-04       Impact factor: 4.530

Review 4.  Treatment of co-occurring anxiety disorders and substance use disorders.

Authors:  R Kathryn McHugh
Journal:  Harv Rev Psychiatry       Date:  2015 Mar-Apr       Impact factor: 3.732

5.  Long-term use of benzodiazepines in participants with comorbid anxiety and alcohol use disorders.

Authors:  Timothy I Mueller; Maria E Pagano; Benjamin F Rodriguez; Steven E Bruce; Robert L Stout; Martin B Keller
Journal:  Alcohol Clin Exp Res       Date:  2005-08       Impact factor: 3.455

Review 6.  Pharmacotherapy of alcoholism in patients with co-morbid psychiatric disorders.

Authors:  Benjamin I Goldstein; Artemis Diamantouros; Ayal Schaffer; Claudio A Naranjo
Journal:  Drugs       Date:  2006       Impact factor: 9.546

7.  Evaluation of buspirone for relapse-prevention in adults with cocaine dependence: an efficacy trial conducted in the real world.

Authors:  Theresa Winhusen; Kathleen T Brady; Maxine Stitzer; George Woody; Robert Lindblad; Frankie Kropp; Gregory Brigham; David Liu; Steven Sparenborg; Gaurav Sharma; Paul Vanveldhuisen; Bryon Adinoff; Eugene Somoza
Journal:  Contemp Clin Trials       Date:  2012-05-19       Impact factor: 2.226

Review 8.  A risk-benefit assessment of buspirone in the treatment of anxiety disorders.

Authors:  J C Pecknold
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

Review 9.  Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities.

Authors:  M Soyka
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

10.  Levetiracetam for the treatment of co-occurring alcohol dependence and anxiety: case series and review.

Authors:  John J Mariani; Frances R Levin
Journal:  Am J Drug Alcohol Abuse       Date:  2008       Impact factor: 3.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.